Sanofi, the top vaccine manufacturer, is collaborating with Bank of America to conduct the demerger process of its consumer healthcare business in India. Sanofi India is currently 60% owned by Sanofi and its wholly-owned subsidiary Hoechst Gmbh. At the same time, the remaining stake is held by a combination of foreign and domestic institutional investors and retail investors.

"Sanofi Pasteur, headquartered in Paris, France, the vaccine division of Sanofi, has established a formidable global footprint with its presence in 150 countries, contributing significantly to the company's position as a major player in the vaccine market." Sanofi Pasteur's vaccine portfolio includes the Meningococcal Conjugate Vaccine, polio, hepatitis B, and influenza vaccine, amongst others.

Sanofi Pasteur's commitment to research and development has resulted in the development of numerous innovative vaccines that have helped improve public health worldwide. The company also produces vaccines for Adenovirus Type 4 And Type 7 Vaccine, travel-related diseases such as yellow fever, and Japanese encephalitis.

Sanofi Pasteur's vaccines are produced using state-of-the-art technology and adhere to strict quality standards​​​​. Sanofi Pasteur demonstrates its unwavering commitment to making high-quality vaccines that meet the most stringent safety and efficacy standards by utilizing Vaccine Storage Medical Refrigerators.

This dedication to safety and effectiveness has helped establish Sanofi Pasteur as a trusted global leader in producing BCG Vaccines, Malaria Vaccines to prevent and treat infectious diseases like TB and malaria, respectively.

The spin-off is expected to create a new standalone company that will be better positioned to compete in the Indian consumer healthcare market, which is highly competitive and rapidly evolving. The move is also expected to provide Sanofi with greater flexibility to invest in its core pharmaceuticals business and pursue new growth opportunities in the healthcare sector.

Sanofi's consumer healthcare business in India includes Over-The-Counter (OTC) Products such as pain relievers, cough and cold medicines, and vitamin supplements. The company has been an essential part of Sanofi's operations in India, with a strong presence in the healthcare market.

The decision to spin off its consumer healthcare business aligns with the broader trend in the pharmaceutical industry, where companies focus on their core businesses and shedding non-core assets. With Bank of America's expertise and support, Sanofi is expected to navigate the demerger process smoothly and create value for all stakeholders. The move also reflects the growing importance of the Indian healthcare market, which is anticipated to proliferate in the coming years.